Collaboration announced on phase 2 trial for oral PTSD treatment
Click Here to Manage Email Alerts
Ananda Scientific and the University of Nebraska Medical Center will conduct a phase 2 clinical trial to assess safety and efficacy of Nantheia ATL5 in the treatment of PTSD in adults, according to a press release from Ananda.
It is expected that 240 participants will be enrolled in the upcoming double-blind, placebo-controlled, randomized trial involving the oral, cannabidiol-based treatment.
The study is being led by principal investigator Mathew Rizzo, MD, chair of the University of Nebraska Medical Center (UNMC) department of neurological sciences and chief physician for neurological services at Nebraska Medicine.
The FDA approved an investigational new drug application for Nantheia ATL5 in January.
“This is our second clinical trial targeting PTSD. We are excited that UNMC’s research team has partnered with us to evaluate our promising drug for this very debilitating condition,” Ananda CEO Sohail R. Zaidi said in the release. “It is an important step in our efforts to provide patients with PTSD with potentially improved therapeutic options.”